🔴 Telix Pharmaceuticals is trading 10.08% down today after announcing a US$1.65 billion ITM acquisition

Telix Pharmaceuticals is trading 10.08% down at A$16.05 after announcing a US$1.65 billion acquisition of ITM Isotope Technologies.

• September 21, 2026 announcement includes issuing 105.8 million Telix shares, leaving existing shareholders with approximately 76.3% ownership after completion.
• Deal assumes US$302 million net debt and may require up to US$700 million additional contingent consideration.
• Reaction appears focused on transaction size, expected dilution and execution risk, not broader market weakness; completion is targeted for end FY2026, subject to shareholder and regulatory approvals.